Insmed (INSM)
NASDAQ: INSM
· Real-Time Price · USD
98.80
1.92 (1.98%)
At close: Jun 13, 2025, 3:59 PM
98.73
-0.07%
After-hours: Jun 13, 2025, 05:50 PM EDT
1.98% (1D)
| Bid | 96.51 |
| Market Cap | 18B |
| Revenue (ttm) | 381.03M |
| Net Income (ttm) | -1.01B |
| EPS (ttm) | -5.93 |
| PE Ratio (ttm) | -16.66 |
| Forward PE | -26.49 |
| Analyst | Buy |
| Ask | 99.2 |
| Volume | 4,722,598 |
| Avg. Volume (20D) | 2,783,020 |
| Open | 96.46 |
| Previous Close | 96.88 |
| Day's Range | 96.01 - 99.66 |
| 52-Week Range | 60.40 - 100.00 |
| Beta | 0.79 |
About INSM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol INSM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for INSM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 days ago
+7.75%
Insmed shares are trading higher after the multipl...
Unlock content with
Pro Subscription
5 days ago
+28.65%
Insmed shares are trading higher after the company announced topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitil inhalation powder met its primary endpoint and all secondary efficacy endpoints.
5 days ago · https://thefly.com
Liquidia price target lowered by $2 at BofA, here's whyLiquidia -2.845 (-15.80%) Insmed +19.21 (+27.19%) 17 Jun
4 days ago · proactiveinvestors.com
Insmed shares surge on positive trial results for pulmonary arterial hypertension therapyInsmed Incorporated (NASDAQ:INSM) shares surged more than 27% after the company unveiled positive results from a Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil ...
